DR info

臨床試験数 : 7 / 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 43

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ALA
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan;
Allogeneic Bone Marrow Transplantation
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Aminolevulinic acid
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan;
DEFEROXAMINE MESILATE
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom;
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom;
DFO
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom;
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom;
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Deferasirox
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Deferoxamine
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom;
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Desferal
   Novartis Pharma Services AG
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
EXJADE
   NOVARTIS FARMA
      2010   -   EUCTR2010-021062-29-IT   Greece;Italy;United Kingdom;
Exjade
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom;
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom;
Fludarabine Phosphate
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
ICL670
   Novartis Pharma Services AG
      2011   -   EUCTR2010-021062-29-GR   Greece;Italy;United Kingdom;
      2010   -   EUCTR2010-021062-29-GB   Greece;Italy;United Kingdom;
      2008   Phase 2   EUCTR2007-000766-20-GB   Italy;United Kingdom;
Methotrexate
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Peripheral Blood Stem Cell Transplantation
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Phosphate
   Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine
      2016   -   JPRN-UMIN000023490   Japan;
   Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
      2016   -   JPRN-UMIN000021407   Japan;
Tacrolimus
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;
Treosulfan
   Fred Hutchinson Cancer Research Center
      2022   Phase 2   NCT04965597   United States;